Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

Nathalie Javidi-Shariﬁ1,2, Elie Traer1,2, Jacqueline Martinez1, Anu Gupta3, Takehiro Taguchi4, Jennifer Dunlap1,5, Michael C. Heinrich1,2,6, Christopher L. Corless1,5, Brian P. Rubin3,7,8, Brian J. Druker1,2,9, and Jeffrey W. Tyner1,10

Abstract

Kinase inhibitors such as imatinib have dramatically improved outcomes for patients with gastrointestinal stromal tumor (GIST), but many patients develop resistance to these treatments. Although in some patients this event corresponds with mutations in the GIST driver oncogenic kinase KIT, other patients develop resistance without KIT mutations. In this study, we address this patient subset in reporting a functional relationship between KIT and FGFR3. FGFR3 expression was increased in imatinib-resistant GIST cells, the growth of which was blocked by RNAi-mediated silencing of FGFR3. Moreover, combining KIT and FGFR3 inhibitors synergized to block the growth of imatinib-resistant cells. Signaling crosstalk between KIT and FGFR3 activated the MAPK pathway to promote resistance to imatinib. Clinically, an IHC analysis of tumor specimens from imatinib-resistant GIST patients revealed a relative increase in FGFR2 levels, with a trend toward increased expression in imatinib-naive samples consistent with possible involvement in drug resistance. Our ﬁndings provide a mechanistic rationale to evaluate existing FGFR inhibitors and multikinase inhibitors that target FGFR3 as promising strategies to improve treatment of patients with GIST with de novo or acquired resistance to imatinib. Cancer Res; 75(5); 880–91. ©2014 AACR.

Introduction

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal neoplasms of the gastrointestinal tract with 5,000 to 6,000 new cases in the United States each year (1). The receptor tyrosine kinase (RTK) KIT is highly expressed and carries activating mutations in most GISTs (2). The majority of GISTs with wild-type KIT have activating mutations in the RTK platelet-derived growth factor receptor α (PDGFRα; refs. 3, 4). Activation of the PI3K pathway downstream of mutant KIT/PDGFRα is essential for GIST cell growth and survival (5). In addition, MAPK pathway signaling is activated downstream of KIT, and plays a pivotal role in tumorigenesis through the stabilization of the transcription factor ETV1 and activation of an oncogenic transcriptional program (6). The introduction of targeted tyrosine kinase inhibitor (TKI) therapy has revolutionized the clinical management of GIST and exempliﬁes the success of targeted therapy in solid tumors, where 80% to 90% of patients with GIST with unresectable or disseminated disease initially attain at least disease stabilization, or complete or partial response to imatinib mesylate (7). However, nearly 50% of GIST cases treated with imatinib develop secondary resistance in the ﬁrst 2 years (8). Most frequently, secondary resistance is due to acquisition of additional mutations in KIT or PDGFRα that decrease the binding afﬁnity for imatinib (9). However, another mechanism that is likely to account for acquired resistance in a subset of GISTs is activation of pathways other than KIT and PDGFRα, thereby bypassing the inhibitory effects of KIT/PDGFRα-targeted small molecules.

RTKs are tightly regulated in normal cells, but frequently acquire transforming functions due to mutation(s), overexpression, and autocrine paracrine stimulation in human cancers. Selective TKIs can block this activity and constitute a promising approach for molecularly guided therapeutics. For example, the FGF signaling network is deregulated in several human cancers, including breast, bladder, prostate, endometrial, and non–small...
cell lung cancer (NSCLC; ref. 10). Receptors may be aberrantly activated through mutations (11, 12), amplifications (13), or fusions (14). The ligands for FGFR receptors have also shown aberrant activity in a variety of cancers. High expression of FGF3, FGF8, and FGFR10 has been reported in breast cancer (15), and correlates with malignant behavior. In prostate cancer (16), FGF2 expressed by stromal cells promotes tumor progression (17). Activation of the FGF signaling axis by FGF8, FGF9, and FGFR10 overexpression is also associated with an aggressive clinical phenotype (18). In addition, FGF2 has recently been shown to mediate resistance to chemotherapy, and, as laid out in this paper, may also provide intrinsic protection of tumor cells in the presence of small-molecule kinase inhibitors.

Materials and Methods

Cell culture and reagents

GIST T1 cells were treated with 10,000 nmol/L imatinib for 2 months and GIST 10R grew out as a resistant colony. The cells were expanded and sequenced for KIT (exon 11–21) and PDGFRα and PDGFRβ (exon 12, 14, and 18). No secondary mutations were found in any of these RRs. GIST T1, GIST 10R, and GIST 882 cells were cultured in RPMI medium supplemented with 15% FBS (Atlanta Biologicals), penicillin/streptomycin (Invitrogen), and Fungizone. GIST T1, GIST 10R, and GIST 882 cells were Sanger sequenced to verify reported activating mutations in KIT. In addition, comparative RNA sequencing of GIST T1 and GIST 10R cells revealed equivalent gene expression and mutational profiles, confirming that these cell lines were derived from the same original clone.

siRNA and kinase inhibitors

The RAPID siRNA library has been previously described (19–21). All siRNAs were from Thermo Fisher Scientific. Human RNAi Technologies and cumulatively target the entire tyrosine kinase gene family as well as NRAS and KRAS (93 genes targeted total). Each well contained a pool of four siRNAs. Cells were aliquoted at 66 μL per well in a 96-well plate and 34 μL of siRNA/OptiMEM/siRNA mixture was added to each well. Oligofectamine and siRNA were used at a ratio of 1:6. For assessment of cell viability and proliferation, cells were subjected to the MTS assay after 96 hours. PD173074, AZD-6244, and IC20 were purchased from Selleck; imatinib and CHIR-258 were purchased from LC Labs.

Immunoblotting

All immunoblotting was performed using standard protocols. Data were analyzed with ImageJ.

GIST tissue samples

All patient specimens were obtained with informed consent of the patients on protocols approved by the Institutional Review Board of Oregon Health and Science University (Portland, OR). To prepare fresh-frozen GIST tissue samples for immunoblotting, tissue was dissected on dry ice using a razor blade. Four shavings per sample were sonicated three times for 3 seconds in 2× Cell Signaling Lysis Buffer.

Real time RT-PCR

RNA was isolated from cells using the RNeasy Mini kit (Qiagen). RNA was transcribed to cDNA using Superscript III reverse transcriptase (Life Technologies), using undiluted RNA. Subsequently, cDNA was diluted 1:4 and quantified via real-time RT-PCR following the TaqMan Gene Expression Assay protocol (Life Technologies). Samples were plated in triplicate, and every assay included a water control.

IHC

Analysis of GI stromal tumor samples was performed by IHC on paraffin-embedded tissue sections. Antigen retrieval was conducted using boiling citrate buffer (10 mmol/L sodium citrate, pH 6.0) for 30 minutes. Please see Supplementary Materials for a complete description of staining and imaging.

Statistical analyses

For cell proliferation assays, a Student's t test was carried out for each treatment condition compared with untreated cells or appropriate controls. The P values for the t tests are indicated by asterisks: *, 0.01 ≤ P < 0.05; **, 0.001 ≤ P < 0.01; ***, P < 0.001. To determine the significance of combination indices to indicate synergy, upper and lower confidence limits were calculated. Data points for combinations with upper confidence limits below 1 were considered synergetic. For further experimental details, see Supplementary Materials and Methods.

Results

siRNA-mediated knockdown identifies FGFR3 dependence in GIST cell lines

GIST T1 cells harbor a heterozygous deletion of KIT exon 11 and consequently exhibit high sensitivity to imatinib with potent suppression of cell proliferation at concentrations ranging from 100 to 1,000 nmol/L. The GIST 10R cell line grew out as a colony after 2 months treatment of GIST T1 cells with 10,000 nmol/L imatinib. Consequently, GIST 10R cells exhibit no IC50 at concentrations of imatinib up to 10,000 nmol/L, although an IC50 is still apparent at 100 nmol/L (Supplementary Fig. S1A). Interestingly, GIST 10R cells do exhibit reduced phosphorylation of KIT and its downstream signaling molecules following treatment with 1,000 nmol/L imatinib (Supplementary Fig. S1B), and no secondary mutations were found in KIT, indicating that drug resistance in GIST 10R cells must be due to alternative mechanisms. The fact that inhibition is equal at equal concentrations of imatinib is likely due to the fact that GIST 10R does not carry additional mutations in KIT that should render this primary drug target less susceptible to inhibition. In addition, comparative RNA sequencing between GIST T1 and 10R revealed no point mutations or remarkable changes in gene expression that would explain drug resistance in these cells. To investigate possible alternative therapeutic targets in these cells, we transfected GIST T1 and 10R cells with a panel of siRNAs that collectively target the entire tyrosine kinase gene family in addition to NRAS and KRAS (93 genes total; refs. 19, 20). As expected, siRNA against KIT significantly reduced the relative number of proliferating GIST T1 cells (Fig. 1A). We also observed a significant reduction in proliferation after silencing of colony stimulating factor 1 receptor, tyrosine kinase 2 (TKY2), and FGFR3. Polo-like kinase 1 plays a critical role in mitosis in all cells and was used as a positive control for effective siRNA-mediated silencing. Interestingly, GIST 10R cells retained residual sensitivity to KIT silencing.
(Fig. 1B); however, silencing of TYK2 and FGFR3 reduced growth more significantly. To confirm reproducible and significant sensitivity to silencing of these genes, we independently assessed cell proliferation after silencing of KIT, FGFR3, and TYK2 compared with nontargeting siRNA. We confirmed the differential effect of KIT siRNA on GIST 10R and T1 cells (Fig. 1C). KIT silencing significantly impacted both cell lines, but this impact was much less pronounced in GIST 10R cells than in GIST T1 cells. We also confirmed that both cell lines were sensitive to FGFR3 silencing to a comparable degree. For reference, FGFR3 phosphorylation and expression levels are compared in all cell line models in Supplementary Fig. S1C. Expression of FGFR3 after treatment of GIST 10R and T1 cells with four individual siRNA duplexes also resulted in reductions of GIST cell viability (Supplementary Fig. S2). To determine whether this impact on relative number of viable cells was predominantly an effect on cell growth or an induction of apoptosis, we also stained cells with Annexin V after silencing of KIT, FGFR3, or TYK2. Although we observed minor increases in Annexin V staining after silencing of each gene, these changes were markedly less than the reduction observed in overall numbers of viable cells, indicating that reduced cell growth is largely responsible for the observed phenotype (Supplementary Fig. S1D).

Inhibition and silencing of FGFR3 and KIT reveal crosstalk

We next sought to understand the role of FGFR3 in maintenance of GIST T1/10R cell growth. First, we treated both cell lines with 1,000 nmol/L imatinib for 2 hours and then detected the active, phosphorylated forms of KIT and FGFR3, as well as total protein, on an immunoblot analysis (Fig. 2A). Surprisingly, in both cell lines, we observed a reduction in phospho-KIT and phospho-FGFR3 after imatinib treatment. To confirm that the reduction in phospho-FGFR3 was not due to an off-target effect of imatinib, we silenced KIT in GIST 10R and again assessed FGFR3 phosphorylation by immunoblot analysis (Fig. 2B). Phosphorylation was again reduced, indicating that FGFR3 activation in GIST cells is dependent on KIT activity.

Next, we asked whether the connection between KIT and FGFR3 was reciprocal, so that FGFR3 inhibition or silencing would affect KIT activity. We treated GIST 10R cells with the FGFR inhibitor PD173074 at 1,000 nmol/L for 2 hours and performed immunoblot analyses (Fig. 2C). Phospho-FGFR3 and total FGFR3 protein levels were markedly reduced after treatment with PD173074. The reduction in total protein may be due to degradation of the receptor after inhibition (Supplementary Fig. S3). Importantly, KIT is not a reported target of PD173074, yet phospho-KIT was reduced after treatment in both cell lines. To rule out direct inhibition of KIT as the source for reduced phosphorylation, we silenced FGFR3 using siRNA in GIST 10R cells and assessed KIT phosphorylation by immunoblot analysis (Fig. 2D). Again, phospho-KIT was reduced after FGFR3 silencing, suggesting that reciprocal crosstalk of KIT, FGFR3, and TYK2 silencing on proliferation of GIST cells (as determined by the MTS assay) The bars represent the mean ± SEM between independent experiments, each containing three replicates (n = 3). The P values for the t tests are indicated by asterisks: *, 0.01 ≤ P < 0.05; **, 0.001 ≤ P < 0.01; ***, P < 0.001. Viability measures for all tested siRNA constructs can be found in Supplementary Table S1.
exists between KIT and FGFR3 in GIST cells. In addition, we stimulated KIT and FGFR3 by the addition of ligand for each receptor (SCF and FGF2, respectively) and observed increased phosphorylation for both KIT and FGFR3 in GIST 10R and, to a lesser degree, in GIST T1 (Fig. 2E and F). Although FGF1 is the prototypic ligand of FGFR3, FGF2 also binds and activates FGFR3 (22). We observed a similar increase in phosphorylation of FGFR3 and KIT as well as β-actin were assessed by immunoblot analysis. FGF Signaling in Imatinib-Resistant GIST.

Coimmunoprecipitation in HEK 293 cells indicates direct crosstalk between KIT and FGFR3

Reciprocal crosstalk between two RTKs may result from indirect interaction (mediated by a common downstream kinase), or direct interaction through the formation of heterodimers or other receptor clustering. To test the hypothesis that the crosstalk between KIT and FGFR3 is direct, we cotransfected HEK 293 cells with plasmids for the overexpression of KIT and FGFR3. After 48 hours, cell lysates were immunoprecipitated with IgG isotype control or antibody against KIT. Whole-cell lysates as well as immunoprecipitates were subjected to immunoblot analysis using an antibody specific for FGFR3.

Figure 2.
Crosstalk between KIT-and FGFR3-signaling after inhibition or stimulation. A, GIST cell lines were treated with 1 μmol/L imatinib (+) or medium (−) for 2 hours. Levels of total and phospho-KIT and FGFR3 as well as β-actin were assessed by immunoblot analysis. Phospho-FGFR3 bands are indicated by arrows. B, GIST cell lines were treated with siRNA against KIT or a nontargeting control pool (nt siRNA) for 96 hours and cell lysates were subjected to immunoblot analysis. C, GIST cell lines were treated with 1 μmol/L of the FGFR-inhibitor PD173074 (+) or media (−) for 2 hours. Levels of total and phospho-KIT and FGFR3 as well as β-actin were assessed by immunoblot analysis. D, GIST cell lines were treated with siRNA against FGFR3 or a nontargeting control pool (nt siRNA) for 96 hours and cell lysates were subjected to immunoblot analysis. E, GIST T1 and 10R cell lines were stimulated with 100 ng/mL SCF for 0, 5, or 15 minutes and cell lysates were subjected to immunoblot analysis. F, GIST T1 and 10R cell lines were stimulated with 100 ng/mL FGF2 for 0, 5, 15, or 20 minutes and cell lysates were subjected to immunoblot analysis. G, HEK 293 cells were transfected with plasmids for the overexpression of KIT and FGFR3. After 48 hours, cell lysates were immunoprecipitated with IgG isotype control or antibody against KIT. Whole-cell lysates as well as immunoprecipitates were subjected to immunoblot analysis using an antibody specific for FGFR3.

Signaling through FGFR3 desensitizes GIST cells to imatinib treatment

We reasoned that presence of ligand, in particular FGF2, in the cell culture media might dampen the response of GIST T1 cells to imatinib. Consequently, we treated GIST T1 cells...
with a gradient of imatinib concentrations with or without a constant concentration of ligand (Fig. 3A). In the absence of ligand, GIST T1 cells were extremely sensitive to imatinib, with an IC_{50} of 40 nmol/L. In the presence of SCF, the IC_{50} was increased slightly, however, at higher concentrations of imatinib, cell proliferation was not improved. In contrast, the
addition of FGF2 increased cell proliferation in the presence of imatinib dramatically, with no IC_{50} even at concentrations as high as 10,000 nmol/L. Of note, the combination of FGF2 and SCF conferred a further increase in viability at low concentrations of imatinib. Similar results were observed using a different, KIT-sensitive GIST-derived cell line, GIST 882 (Fig. 3B). We also cultured GIST T1 cells with 1,000 nmol/L imatinib in the presence or absence of 10 ng/mL SCF or FGF2 (Fig. 3C). Viable cells were counted every 2 to 3 days for 19 days. As expected, culture with SCF did not confer any growth advantage over cells cultured with imatinib and a vehicle control. The addition of FGF2, however, increased the number of viable cells starting at day 4. Importantly, cells not only persisted in the culture, but, after a lag phase, continued to divide and exceeded the number initially plated on day 0. We hypothesized that the desensitization of GIST cells to imatinib is indeed mediated through the interaction between KIT and FGFR3, and not the result of an alternative survival pathway replacing KIT signaling. To this end, we measured GIST T1 cell growth after KIT silencing in the presence or absence of FGF2 with the hypothesis that presence of KIT protein would be required for FGF2 rescue (Fig. 3D). As predicted, rescue of cell growth by FGF2 was ineffective after KIT knockdown, indicating that FGF2 rescue requires presence of both KIT and FGFR3. We also showed that inhibition of FGFR3 by PD173074, which inhibits GIST T1 cell proliferation with an IC_{50} of 300 nmol/L, can be partially reversed by the addition of SCF (Supplementary Fig. S5) and that SCF rescue is ineffective after silencing of FGFR3 (Fig. 3D). To test whether desensitization to imatinib is indeed mediated by FGFR3, we performed siRNA knockdown of FGFR1, FGFR2, and FGFR3 in GIST T1, and subsequently treated with imatinib and FGF2 (Fig. 3E). Knockdown of FGFR receptors was confirmed via real-time RT-PCR (Supplementary Fig. S6). FGF2 rescue of imatinib sensitivity remained effective after FGFR1 and FGFR2 silencing; however, FGFR3 silencing ablated the response to FGF2, implicating FGFR3 but not FGFR1 or FGFR2 in FGF2-mediated drug resistance. We next treated GIST T1 cells with 0, 50, or 500 nmol/L imatinib and stimulated cells with SCF or FGF2. At baseline, KIT phosphorylation was responsive to both SCF and FGF2 stimulation. The response to SCF was conserved in the context of 50 nmol/L imatinib treatment, but was markedly decreased after treatment with 500 nmol/L imatinib. In contrast, FGF2 still restored KIT phosphorylation at 500 nmol/L (Fig. 3F). To ensure that this observation was not specific to the cell line GIST T1, we repeated this experiment in the cell line GIST 882 (Fig. 3G). Again, we observed that KIT phosphorylation in GIST 882 was completely ablated at 500 nmol/L imatinib without FGF2 stimulation, but could be partially restored by the addition of FGF2. We subsequently sought to determine the effects of FGF2 stimulation on downstream signaling in the setting of imatinib treatment (Fig. 3H). Analysis of AKT and MAPK pathway activation revealed that both pathways are inhibited after imatinib treatment. However, although AKT phosphorylation remained inhibited after the addition of FGF2, MEK1/2 and ERK1/2 phosphorylation was restored.

Combined inhibition of KIT and FGFR3 is highly synergistic in imatinib-resistant GIST cells

We hypothesized that combination treatment using imatinib and the selective FGFR inhibitor PD173074 may restore imatinib sensitivity in resistant GIST cells. Accordingly, we performed dose–response curves in the imatinib-resistant GIST 10R cells using imatinib and PD173074 alone as well as a constant, equimolar ratio combination of the two drugs (Fig. 4A). We then determined the combination index (CI) for each dose point using the Chou–Talalay method to quantify synergy. Figure 4B shows CI values plotted against the log of drug dose. Over the entire dosing curve, the CI values ranged from 0.0005 to 0.004, indicating an extremely high degree of synergy between the two drugs.

We next wanted to determine whether signaling pathways activated downstream of FGFR3 might also exhibit synergy with KIT inhibition. To this end, we treated GIST 10R cells with combinations of imatinib and PLX-4720, a B-Raf inhibitor (Supplementary Fig. S7), AZD-6244, a MAPK inhibitor (Fig. 4C), and PI103, a PI3K inhibitor (Fig. 4D). Combination of imatinib with inhibitors of the RAF/MAPK pathway exhibited significant synergy at all concentrations tested. In contrast, combination of imatinib with inhibitors of the PI3K-akt pathway did not result in synergy with imatinib. Combined treatment with imatinib and AZD-6244, in particular, led to a decrease in cell growth similar to that observed after imatinib and PD173074 treatment, suggesting that the MAPK pathway is a key mediator of imatinib resistance in GIST 10R cells.

The MAPK signaling pathway is activated in GIST 10R cells in response to imatinib

We performed immunoblot analysis to assess phosphorylation of AKT, c-Raf, MEK, and ERK in GIST 10R and T1 cells after 2-hour treatment with 1,000 nmol/L imatinib (Fig. 5A). In both cell lines, AKT phosphorylation was reduced less markedly after treatment. However, we observed divergent effects on MAPK pathway activation. Phosphorylation of c-Raf was reduced less markedly in GIST 10R compared with GIST T1 cells. Even more strikingly, phosphorylation of MEK and ERK was abolished in GIST T1 after imatinib treatment, but increased in GIST 10R. To determine whether this feedback mechanism could be solely regulated at the receptor level, or whether it might also be regulated after direct inactivation of the downstream PI3K signaling, we treated GIST 10R cells with the PI3K inhibitor PI103 and asked whether the same increased phosphorylation of MAPK signaling resulted (Fig. 5B). No increase in c-Raf, MEK, or ERK phosphorylation was observed after inhibition of PI3K. To assess whether FGF receptors are involved in mediating this MAPK feedback mechanism, we inhibited KIT and FGFRs, either by the dual inhibitor CHIR-258 (dovitinib; Fig. 5C), or by a combination of imatinib and PD173074 (Fig. 5D). We found that MAPK activation was abrogated in both cases, providing a mechanistic basis for the synergy observed in Fig. 4.

FGF2 is overexpressed in GIST 10R cells and is increased in tumor tissue after imatinib treatment

Because our data suggest that FGF2 can promote imatinib resistance in GIST cells, we wanted to determine whether FGF2 levels are higher in GIST 10R than GIST T1 cells and whether this might underlie the resistance of GIST 10R cells to imatinib. It is well recognized that FGF2 associates with heparan sulfate in the extracellular matrix. We were thus unable to detect it in supernatant but found it present in cell lysate. Evaluation of FGF2 protein levels did reveal increased levels of FGF2 in GIST 10R cells compared with GIST T1 (Fig. 6A). Subsequently, we
investigated whether silencing of FGF2 in GIST 10R cells changes cell growth when compared with treatment with nontargeting siRNA. Indeed, we observed a significant decrease in cell growth after GIST 10R cells were treated with FGF2 siRNA (insert in Fig. 6B). We next asked whether siRNA-mediated knockdown of FGF2 would resensitize these cells to imatinib. Silencing of FGF2 dramatically shifted the IC50 for imatinib in GIST 10R cells (Fig. 6B), indicating that FGF2 contributes to imatinib resistance in GIST 10R and that the inhibition of FGF signaling restores the response to imatinib in a resistant GIST cell line. Knockdown of FGF2 expression was confirmed via real-time RT-PCR (Supplementary Fig. S8). We sought to examine whether increased levels of FGF2 correlated with KIT activation in GIST patient samples. We obtained a panel of six frozen tissue specimens from GI stromal tumors with confirmed activating mutations in KIT exon 11. Five of the tumors were treatment naive at the time of biopsy, while one patient had received 4 to 5 weeks of imatinib before the tumor being removed. The treatment was discontinued 3 to 4 days before surgery. We performed immunoblot analyses for activated KIT and FGFR, as well as FGF2 levels in these samples (Fig. 6C) and observed increased FGF2 in specimen TB-7248, which had been exposed to imatinib. The pan-phospho-FGFR antibody yielded immunoblot analyses with lower background and was thus chosen here for use on tumor lysates. Concurrent with high FGF2 levels, we observed a high degree of phosphorylated KIT and FGFR. This observation is consistent with our model of FGF2-mediated reactivation of KIT. We sought to validate these findings in a larger number of GIST samples by performing IHC staining for FGF2 on ten sections of formalin-fixed paraffin-embedded tissue (Fig. 6D). An illustration of the quantification process is provided in Supplementary Fig. S9. Samples not previously exposed to treatment were segregated by mitotic rate and tumor size according to the Fletcher risk table into low-risk and intermediate/high-risk categories. Figure 6E–G provides examples of IHC staining in treatment naive, low-risk disease, as well as two cases of imatinib exposed tumor samples. Overall, low risk was associated with low FGF2 staining, whereas intermediate/high-risk and treatment exposure or resistance were associated with elevated levels, warranting further study of FGF2 levels in even larger cohorts of primary GIST patient specimens in the future.

Discussion

Our study describes for the first time a functional cooperation between FGFR3 and KIT in human GIST and analyzes the molecular mechanisms that underlie this cooperation. The findings provide insight into the protective potential of FGF signaling in GIST and into the signal transduction pathways that mediate resistance to small-molecule inhibitors of KIT in these tumors. Moreover, this represents a new mechanism of resistance in this setting that can account for GIST patients progressing on imatinib in the absence of a secondary resistance mutation in KIT.

In addition to the paracrine action of cancer cell-secreted FGF2 on endothelial cells, FGF2 can provide autocrine prosurvival and mitogenic signals, and confer resistance to chemotherapeutic drugs. FGF2 (over)expression has been observed after chemoradiation and is correlated with...
recurrence risk in some cancers. FGF2 modulates the response of a wide range of tumor types, such as neuroblastoma, breast cancer, melanoma, and NSCLC to chemotherapy or radiation (23–26). There are also accounts of FGF signaling involvement in resistance to targeted therapy, for example, through derepression of FGFR2 and FGFR3 in NSCLC cell lines, which leads to resistance to EGFR inhibitor therapy (27). Although the mechanism is not clear in every setting, FGF2 protects both NSCLC and endothelial cells from apoptosis in a Raf-dependent manner after chemotherapy or VEGFR inhibition.

Figure 5.
The MAPK pathway is upregulated downstream of FGFRs in resistant GIST cells in response to imatinib. A, GIST T1 and GIST 10R cells were treated with imatinib for 2 hours and cell lysates were subjected to immunoblot analysis using antibodies specific for total or phospho-AKT, c-Raf, MEK1/2, ERK1/2, or β-actin. B–D, GIST 10R cells were treated with the PI3K inhibitor PI103 (B), the multikinase inhibitor CHIR-258 for 2 hours and cell lysates were subjected to immunoblot analysis (C), or a combination of imatinib and PD173074 (D).
FGF2 overexpression is not only associated with resistance to chemotherapy and radiotherapy, but also correlates with an increased risk of recurrence and reduced overall survival. The array of tumor types and treatments to which FGF2 is connected suggests a global protective role for this ligand, which is in line with FGF2’s role in normal tissues during injury and inflammation.

Here, we present one of the first accounts of FGF2-mediating resistance to targeted therapy. Recently, activation of FGFR3 and the downstream MEK/ERK pathway was also implicated in resistance to a targeted agent, the B-RAF inhibitor vemurafenib, in melanoma (25). The protective effect of FGF2 in this setting is mediated by the MAPK pathway and downstream activation of ribosomal protein S6 kinase (26). Similarly, an autocrine signaling loop was identified in NSCLC, where FGFRs and their ligands were coexpressed and provided an alternative pathway to EGFR signaling in cells treated with gefitinib (32). This correlates well with our finding that MAPK pathway members are preferentially activated after FGF2 stimulation in the presence of imatinib in GIST T1 cells. Similarly, this pathway remained active in GIST 10R cells during imatinib treatment, and these cells could be resensitized by combined imatinib and MAPK inhibitor treatment. The RAF/MEK/ERK signaling pathway is already recognized as an important driver of cell proliferation, survival, and angiogenesis in GIST, as evidenced by an ongoing phase II multicenter trial of the Raf inhibitor sorafenib in imatinib- and sunitinib-resistant GIST. Selective inhibition of this pathway also inhibited proliferation and induced apoptosis and cell-cycle arrest in patient-derived GIST xenograft lines (33). Taken together with our observations, this underscores the potential of the Raf/MEK/ERK signaling pathway as potential future targets of molecular therapy in GIST.

We propose that, in addition to preferential activation of the MAPK pathway, FGFR3 activation partially restores KIT activity. In the setting of overexpression of both receptors, we demonstrated an interaction between the two receptors. Although these data are supportive of a direct interaction between KIT and FGFR3, this is only one mechanism potentially underlying the crosstalk observed in GIST cells, and other possibilities such as the involvement of downstream mediators should not be discarded. Receptor crosstalk and heterodimerization to circumvent targeted therapy have been explored extensively in the setting of EGFR inhibition. EGF can interact with other RTKs such as MET, ERBB2, and IGF-1R (34). These mechanisms were identified at the clinical and preclinical level in NSCLC and breast cancer. Overexpression and activation of EGFR can promote transphosphorylation of MET in lung and epidermal carcinoma cell lines. Activation of MET occurs in an EGFR-ligand dependent manner in the setting of EGFR overexpression, or independently of ligand in glioblastomas expressing a constitutively active EGFR variant. Xenograft models of glioblastoma require targeting of both EGFR and MET to achieve growth inhibition (34). The crosstalk between KIT and FGFR3 we present in this paper involves two hitherto unconnected signaling pathways, which are highly relevant to human cancers. Our findings are consistent with the biology reported for crosstalk in other systems. Although no previous reports exist of transactivation between KIT and FGFR3, there is evidence that FGFRs can crosstalk with other RTKs. For example, the cytoplasmic domains of FGFRs and EphA4 can interact and transphosphorylate each other (35).

In light of the propensity of FGF2 to desensitize GIST cells to the short- and long-term effects of imatinib, we suggest that FGF2 expression in treated tumors provides the basis for the development of resistance. Future studies should determine the mechanism of FGF2 upregulation and examine the dynamics of FGF2 expression with imatinib treatment. This would provide valuable information to identify patient populations who may be at risk of FGF-mediated resistance, either by constitutive overexpression or by sustained upregulation in response to therapy. Our observations are an added incentive to pursue targeted treatment that combines inhibition of KIT with antagonism of protective signaling from autocrine loops or the tumor stroma. This strategy could be especially powerful with screening to identify patients at risk for microenvironment-induced resistance.

In summary, we show for the first time that the FGFR3 pathway crosstalks with KIT, and that FGF2 mediates survival and outgrowth of GIST cells during imatinib treatment. We further elucidate the molecular mechanisms of FGF2-mediated drug rescue. Our data suggest that incorporation of FGFR3 inhibitors to combination therapeutic regimens may be beneficial in overcoming clinical resistance to targeted therapies for some patients with GIST.

Disclosures of Potential Conflicts of Interest

M.C. Heinrich is a consultant in Novartis, Ariad, MolecularMD, and Pherex, reports receiving commercial research support from AROG, has received honoraria from speakers’ bureaus from Novartis, and has ownership interest (including patents) in Novartis. B.P. Rubin received honoraria from speakers’ bureaus from Novartis. B.J. Drucker is a scientific advisory board member for Lorus Therapeutics and received commercial research support from Oncotide Pharmaceuticals subcontract from NIH SCTR, Novartis clinical trial funding, Bristol-Myers Squibb clinical trial funding, ARIAD clinical trial funding, has ownership interest in OHSU invention #843, OHSU invention #0996, OHSU invention #0606, MolecularMD, Blueprint Cytosystems, and Cellvizio with royalties. M.C. Heinrich, B.P. Rubin, and B.J. Drucker are listed as inventors on multiple US and international patents. M.C. Heinrich and B.J. Drucker are shareholders in OHSU invention #0606, MolecularMD, Blueprint Cytosystems, and Cellvizio. B.J. Drucker declares other activities of interest (including patents) in Novartis, Ariad, MolecularMD, and Pherex. D. Wang reports receiving commercial research support from Andes Therapeutics, has received honoraria from speakers’ bureaus from Novartis, and has ownership interest (including patents) in Novartis. O. Borras reports receiving commercial research support from Lorus Therapeutics, has received honoraria from speakers’ bureaus from Novartis and Shire, and has ownership interest (including patents) in Novartis. C. Banting reports receiving commercial research support from Roche, has received honoraria from speakers’ bureaus from Novartis, and has ownership interest (including patents) in Novartis. O. Yoon reports receiving commercial research support from Novartis, Bristol-Myers Squibb, has received honoraria from speakers’ bureaus from Novartis, and has ownership interest (including patents) in Novartis. M. Morin reports receiving commercial research support from onemed, has received honoraria from speakers’ bureaus from Novartis, and has ownership interest (including patents) in Novartis. E. Bulte declares other activities of interest (including patents) in Novartis, Waltrue, and MolecularMD, and is a shareholder in M.C. Heinrich has received commercial research support from AROG, has received honoraria from speakers’ bureaus from Novartis, and has ownership interest (including patents) in Novartis. M.C. Heinrich, B.P. Rubin, and B.J. Drucker are listed as inventors on multiple US and international patents. M.C. Heinrich and B.J. Drucker are shareholders in OHSU invention #0606, MolecularMD, Blueprint Cytosystems, and Cellvizio with royalties. M.C. Heinrich, B.P. Rubin, and B.J. Drucker are listed as inventors on multiple US and international patents. B.J. Drucker declares other activities of interest (including patents) in Novartis, Ariad, MolecularMD, and Pherex. D. Wang reports receiving commercial research support from Andes Therapeutics, has received honoraria from speakers’ bureaus from Novartis and Shire, and has ownership interest (including patents) in Novartis. O. Borras reports receiving commercial research support from Lorus Therapeutics, has received honoraria from speakers’ bureaus from Novartis and Shire, and has ownership interest (including patents) in Novartis. C. Banting reports receiving commercial research support from Roche, has received honoraria from speakers’ bureaus from Novartis, and has ownership interest (including patents) in Novartis. O. Yoon reports receiving commercial research support from Novartis, Bristol-Myers Squibb, has received honoraria from speakers’ bureaus from Novartis, and has ownership interest (including patents) in Novartis. M. Morin reports receiving commercial research support from onemed, has received honoraria from speakers’ bureaus from Novartis, and has ownership interest (including patents) in Novartis. E. Bulte declares other activities of interest (including patents) in Novartis, Waltrue, and MolecularMD, and is a shareholder in
Medicines, Atilifipio via Dana-Farber Cancer Institute for 4G10, and is a consultant/advisory board member for MolecularxMD, Blueprint Medicines, Gilead Sciences, Cell Therapeutics, Inc., AstraZeneca, Cyline Pharmaceuticals, Lorus Therapeutics, and Drug Discovery and Development Center, Biomedical Sciences Institutes. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: N. Javidi-Shari, M.C. Heinrich, C.L. Corless, B.P. Rubin, J.W. Tyner
Development of methodology: N. Javidi-Shari, E. Traer, M.C. Heinrich, J.W. Tyner
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): N. Javidi-Shari, J. Martinez, A. Gupta, B.J. Druker, J.W. Tyner
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): N. Javidi-Shari, E. Traer, J. Dunlap, M.C. Heinrich, C.L. Corless, B.J. Druker, J.W. Tyner
Writing, review, and/or revision of the manuscript: N. Javidi-Shari, E. Traer, M.C. Heinrich, C.L. Corless, B.P. Rubin, B.J. Druker, J.W. Tyner

Grant Support

N. Javidi-Shari was supported by the Oregon Clinical and Translational Research Institute (OCTRI), grant number TL1 RR024159 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH, and NIH Roadmap for Medical Research. B.J. Druker was an investigator of the Howard Hughes Medical Institute. J.W. Tyner was supported by grants from the V Foundation for Cancer Research, The Leukemia and Lymphoma Society, the Gabrielle’s Angel Foundation for Cancer Research, and the National Cancer Institute (5R00CA151457-04; 1R01CA183974-01). B.P. Rubin and A. Gupta were supported by the Life Raft Group.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 25, 2014; revised October 14, 2014; accepted November 2, 2014; published OnlineFirst November 28, 2014; DOI: 10.1158/0008-5472.CAN-14-0573

References


Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

Nathalie Javidi-Sharifi, Elie Traer, Jacqueline Martinez, et al.


Updated version
Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-14-0573

Supplementary Material
Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2014/11/27/0008-5472.CAN-14-0573.DC1

Cited articles
This article cites 35 articles, 12 of which you can access for free at: http://cancerres.aacrjournals.org/content/75/5/880.full.html#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at: /content/75/5/880.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.